Search Results - joel+levine

1 Results

Sort By:

Single Chain Antibody (Mab69) Against the NG2 Proteoglycan

AAV based viral vectors that express either AAV-NG2Ab or AAV-NT3 have been shown to provide improved recovery of motor function in models. Background: Spinal Cord Injury (SCI) affects nearly 270,000 Americans and is a common cause of permanent disability and death in children and adults. Despite being a significant burden to the patients, society...

Published: 9/4/2024 | Inventor(s): Joel Levine, Victor Arvanian

Keywords(s): Technologies

Category(s): Campus > Stony Brook University, Technology Classifications > Antibodies, Technology Classifications > Gene Therapy and Viral Vectors, Technology Classifications > Therapeutics